<DOC>
	<DOCNO>NCT02054390</DOCNO>
	<brief_summary>Metabolic syndrome ( MS ) report risk cardiovascular event . The aim present cohort study investigate whether ACEi therapy reduces rate periprocedural myocardial injury ( PPMI ) elective percutaneous coronary intervention ( PCI ) among patient metabolic syndrome .</brief_summary>
	<brief_title>Angiotensin Converting Enzyme Inhibitors Periprocedural Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>1. metabolic syndrome 2. elective percutaneous coronary intervention angiographically successful stent implantation 1. acute coronary event 2. renal failure 3. need use IV glycoprotein IIb/IIIa receptor inhibitor exclude 4. leave main coronary artery disease 5. chronic total occlusion 6. high level baseline CKMB troponin 7. contraindication aspirin , clopidogrel ACEi treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Angiotensin convert enzyme inhibitor</keyword>
	<keyword>inflammation</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>myonecrosis</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>periprocedural myocardial injury</keyword>
</DOC>